CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 35 enrolled
Drug / intervention
Epigallocatechin-3-gallate (EGCG)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03928847
NCT03928847Early Ph 1Completed
CompareCT.gov

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Hal Chapman·interventional·Posted Apr 26, 2019·Updated Dec 22, 2022

In Brief

A Early Phase 1 clinical trial evaluating Epigallocatechin-3-gallate (EGCG) for Idiopathic Pulmonary Fibrosis. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This is a two part study. In the first part, the pharmacokinetic profile of Epigallocatechin-3-gallate (EGCG) in normal human volunteers given a single oral dose will be determined to set the dose for the second part of the study. In the second part of this study, lung biopsy fragments and urine samples from patients with interstitial lung disease treated with EGCG will be evaluated in biochemical assays and compared to samples from untreated control patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Early Ph 1CompletedFinished
201820192020202120222023202420252026
First PostedApr 26, 2019
Enrollment StartDec 1, 2017
Primary CompletionMay 31, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.2 years ago

Interventions

Epigallocatechin-3-gallate (EGCG)drug

Epigallocatechin-3-gallate (EGCG) capsules